Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease

ClinicalTrials.gov ID: NCT00160706

Public ClinicalTrials.gov record NCT00160706. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 12:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III Multi-national, Multi-centre, Open Label, Safety Study to Assess the Safety of Re-exposure After a Variable Interval and Subsequent Chronic Therapy With the Humanised Anti-TNF PEG Conjugate CDP870 400 mg sc, (Dosed at Weeks 0, 2 and 4 Then Every 4 Weeks), in the Treatment of Patients With Active Crohn's Disease Who Have Previously Been Withdrawn From Studies CDP870-031 or CDP870-032 Due to an Exacerbation of Crohn's Disease.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A follow-on safety study in subjects with Crohn's Disease who have previously been withdrawn from the double-blind study CDP870-031 \[NCT00152490\] or CDP870-032 \[NCT00152425\] due to an exacerbation of Crohn's Disease.

Study identification

NCT ID
NCT00160706
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
UCB Pharma SA
Industry
Enrollment
310 participants

Conditions and interventions

Interventions

Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2004
Primary completion
Apr 30, 2012
Completion
Apr 30, 2012
Last update posted
Aug 6, 2018

2004 – 2012

United States locations

U.S. sites
41
U.S. states
22
U.S. cities
40
Facility City State ZIP Site status
45102 Birmingham Alabama
45028 Huntsville Alabama
45044 Little Rock Arkansas
45095 Orange California
45101 San Francisco California
45130 Colorado Springs Colorado
45094 Gainesville Florida
45005 Hialeah Florida
45087 Miami Florida
45004 North Miami Beach Florida
45016 Chicago Illinois
45037 Indianapolis Indiana
45019 Lexington Kentucky
45033 Chevy Chase Maryland
45013 Laurel Maryland
45083 Rochester Minnesota
45108 Jefferson City Missouri
45035 Berlin New Jersey
45009 Great Neck New York
45070 New York New York
45145 Greenville North Carolina
45067 High Point North Carolina
45003 Raleigh North Carolina
45040 Winston-Salem North Carolina
45081 Cincinnati Ohio
45091 Cincinnati Ohio
45054 Dayton Ohio
45025 Mayfield Heights Ohio
45039 Oklahoma City Oklahoma
45041 Tulsa Oklahoma
45093 Hershey Pennsylvania
45113 Germantown Tennessee
45119 Nashville Tennessee
45022 Houston Texas
45073 San Antonio Texas
45139 Salt Lake City Utah
45052 South Ogden Utah
45134 Charlottesville Virginia
45078 Christiansburg Virginia
45109 Norfolk Virginia
45141 Seattle Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 100 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00160706, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 6, 2018 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00160706 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →